Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 785 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Gene Expression Clear all

Conditions: Asthma
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 1995
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Low Birth Weight Infant
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: Up to 5 Days
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2014
U.S. locations: 2
States / cities: Salt Lake City, Utah

Conditions: Dermatomyositis, Polymyositis
Interventions: Infliximab; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 1 Diabetes, Celiac Disease
Interventions: Sera and whole blood sampling, Differential Gene Expression (DGE); Diagnostic Test
Lead sponsor: Sanford Health; Other
Eligibility: 0 Minutes to 17 Years
Enrollment: 33,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2031
U.S. locations: 4
States / cities: Bemidji, Minnesota • Bismarck, North Dakota • Fargo, North Dakota + 1 more

Conditions: Hepatitis B
Interventions: Hepatitis B Vaccine (Recombinant); Biological
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Cancer, Breast Cancer, Prostate Cancer, Tumors (Others), Ovarian Cancer
Interventions: MVA-brachyury- TRICOM; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Melanoma, Colon Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Hepatocellular Cancer
Interventions: National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Arthritis, Rheumatoid
Interventions: Not listed
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 25 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 4
States / cities: Birmingham, Alabama • Los Angeles, California • Omaha, Nebraska + 1 more

Conditions: Chronic Low Back Pain (CLBP)
Interventions: Empowering Pain Psychology Access and Collaboration (EPPAC), Usual Care Pain Psychology Evaluation; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Endometrial Cancer, Ovarian Cancer
Interventions: PD-1/PDL-1 staining; Diagnostic Test
Lead sponsor: RWJ Barnabas Health at Jersey City Medical Center; Other
Eligibility: Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Jersey City, New Jersey

Conditions: Sepsis, Non-Infectious Systemic Inflammatory Response Syndrome
Interventions: SeptiCyte (various); Diagnostic Test
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 1 Month to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Thyroid Cancer
Interventions: Bexarotene; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hypertrophic Cardiomyopathy
Interventions: TN-201; Genetic
Lead sponsor: Tenaya Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 10
States / cities: La Jolla, California • San Francisco, California • Atlanta, Georgia + 7 more

Conditions: Healthy Volunteer, Prostate CA
Interventions: Piflufolastat F18; Drug
Lead sponsor: Akiva Mintz; Other
Eligibility: 18 Years to 120 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Englewood, New Jersey

Conditions: Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Acute Leukemia of Ambiguous Lineage
Interventions: Chemosensitivity Assay, Cytology Specimen Collection Procedure, Gene Expression Analysis, Genetic Variation Analysis, In Vitro Sensitivity-Directed Chemotherapy; Other · Genetic · Drug
Lead sponsor: University of Washington; Other
Eligibility: 3 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Tinnitus
Interventions: The Inhibitor™ Tinnitus Masking Device; Device
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Gastrointestinal Stromal Tumors
Interventions: Imatinib Mesylate (Gleevec); Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prematurity; Extreme, Feeding Disorder Neonatal, Breast Milk Expression, Growth Failure, Microbial Colonization
Interventions: Protein-enriched human milk diet, Usual human milk diet; Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Day to 4 Days
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Human Milk Microbiome, Bacterial Growth
Interventions: Sterile pump set-up, Mother's Own pump set-up; Device
Lead sponsor: Cornell University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Ithaca, New York

Conditions: Chronic Hepatitis C, Obesity
Interventions: Not listed
Lead sponsor: Palo Alto Veterans Institute for Research; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Melanoma
Interventions: EGIR Tape; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Advanced Solid Tumors
Interventions: Conjugated Linoleic Acid, Conjugated Linoleic Acid; Dietary Supplement · Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Breast Feeding, Breast Milk Expression, Stress
Interventions: Not listed
Lead sponsor: University of Rochester; Other
Eligibility: Female only
Enrollment: 27 participants
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Rochester, New York

Search by objective public record fields.

Role of T-Cells in Asthma

Platelet-activating Factor Acetylhydrolase (Paf-ah) Gene Expression

Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis

General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care Delivery

Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers

Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)

Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer

Effects Of Prednisolone On Rheumatoid Arthritis Patients

Empowering Pain Psychology Access and Collaboration (EPPAC) to Improve Treatment Engagement Among Medicaid-insured Adults With Chronic Low Back Pain

Tumor Grade Determines PD-1/PDL-1 Expression

Gene Expression Objective Definition of Early Sepsis In Children

A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression

Study of the P16 Gene as a Predictor of Myelosuppression in Breast Cancer Patients

Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

Ultralow Dose PET Imaging for PSMA Expression

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

Inhibitor Masking Device & Sodium Channel, Voltage Gated, Type IX Alpha Subunit (SCN9) Gene Expression

Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST

Early Protein Supplementation in Extremely Preterm Infants Fed Human Milk

Milk in Life Conditions (MiLC): Bacterial Composition of Human Milk Pumped and Stored in "Real-Life" Conditions

Microarray Analysis of IFN-Induced Gene Expression in Obese and Non-Obese Patients With Chronic Hepatitis C

Early Diagnosis of Melanoma Using Expression Profiling and Non-Invasive Sampling of Skin Cells

A Molecular Pharmacodynamic Dose-titration Trial of Conjugated Linoleic Acid (CLA; Clarinol®) in Patients With Advanced Solid Tumors

Stress and Breast Milk Study In the Neonatal Intensive Care Unit